{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:35:25Z","timestamp":1783478125567,"version":"3.55.0"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have produced significant survival benefit across many tumor types. However, immune-related adverse events are common including autoimmune responses against different endocrine organs. Here, a case of ICI-mediated hypoparathyroidism focusing on long-term follow-up and insights into its etiology is presented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case and methods<\/jats:title>\n                  <jats:p>A 73-year-old man developed severe symptomatic hypocalcemia after the initiation of ipilimumab and nivolumab for the treatment of metastatic melanoma. Hypoparathyroidism was diagnosed with undetectable intact parathyroid hormone (PTH). Immunoprecipitation assays, ELISAs, and cell-based functional assays were used to test the patient for antibodies against the calcium-sensing receptor (CaSR). NACHT leucine-rich repeat protein 5 (NALP5) and cytokine antibodies were measured in radioligand binding assays and ELISAs, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The patient\u2019s symptoms improved with aggressive calcium and vitamin D supplementation. At 3\u2009years and 3\u2009months since the diagnosis of hypoparathyroidism, PTH was still inappropriately low at 7.6\u2009pg\/mL, and attempted discontinuation of calcium and calcitriol resulted in recurrent symptomatic hypocalcemia. Analysis for an autoimmune etiology of the patient\u2019s hypoparathyroidism indicated that CaSR antibodies were negative before treatment and detected at multiple time points afterwards, and corresponded to the patient\u2019s clinical course of hypoparathyroidism. CaSR antibodies purified from the patient\u2019s serum activated the human CaSR. The patient was seronegative for NALP5 and cytokine antibodies, indicating that their hypoparathyroidism was not a manifestation of autoimmune polyendocrine syndrome type 1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The etiology of hypocalcemia is likely autoimmune hypoparathyroidism caused by the development of CaSR-activating antibodies that might prevent PTH release from the parathyroid.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-000687","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T02:35:15Z","timestamp":1593052515000},"page":"e000687","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up"],"prefix":"10.1136","volume":"8","author":[{"given":"Ramona","family":"Dadu","sequence":"first","affiliation":[{"name":"Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa E","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van A","family":"Trinh","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Helen","family":"Kemp","sequence":"additional","affiliation":[{"name":"Oncology and Metabolism, The University of Sheffield, Sheffield, South Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha D","family":"Cubb","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-1517","authenticated-orcid":false,"given":"Sapna","family":"Patel","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M","family":"Simon","sequence":"additional","affiliation":[{"name":"Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M","family":"Burton","sequence":"additional","affiliation":[{"name":"Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Tawbi","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"2025100312280409000_8.1.e000687.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100312280409000_8.1.e000687.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2025100312280409000_8.1.e000687.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2025100312280409000_8.1.e000687.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025100312280409000_8.1.e000687.5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025100312280409000_8.1.e000687.6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100312280409000_8.1.e000687.7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-Mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100312280409000_8.1.e000687.8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116"},{"key":"2025100312280409000_8.1.e000687.9","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"},{"key":"2025100312280409000_8.1.e000687.10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100312280409000_8.1.e000687.11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report","volume":"14","author":"Umeguchi Takenoshita","year":"2018","journal-title":"J Oncol Pract"},{"key":"2025100312280409000_8.1.e000687.12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2466"},{"key":"2025100312280409000_8.1.e000687.13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701527"},{"key":"2025100312280409000_8.1.e000687.14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031054"},{"key":"2025100312280409000_8.1.e000687.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706487"},{"key":"2025100312280409000_8.1.e000687.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030289"},{"key":"2025100312280409000_8.1.e000687.17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1080"},{"key":"2025100312280409000_8.1.e000687.18","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100312280409000_8.1.e000687.19","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100312280409000_8.1.e000687.20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.autrev.2014.01.044","article-title":"Diagnosis and classification of autoimmune parathyroid disease","volume":"13","author":"Betterle","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2025100312280409000_8.1.e000687.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1533209100"},{"key":"2025100312280409000_8.1.e000687.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2025100312280409000_8.1.e000687.23","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123"},{"key":"2025100312280409000_8.1.e000687.24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100312280409000_8.1.e000687.25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"Iga nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med"},{"key":"2025100312280409000_8.1.e000687.26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"2025100312280409000_8.1.e000687.27","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1452-4"},{"key":"2025100312280409000_8.1.e000687.28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798"},{"key":"2025100312280409000_8.1.e000687.29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12094-019-02273-x","article-title":"SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)","volume":"22","author":"Majem","year":"2020","journal-title":"Clin Transl Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:28:16Z","timestamp":1759519696000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,24]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/jitc-2020-000687"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000687","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}